Fig. 4: Identification of an inhibitor against SMNDC1’s Tudor domain.
From: Pharmacological perturbation of the phase-separating protein SMNDC1
a Scheme of AlphaScreen set-up with the NMR-structure of SMNDC1’s Tudor domain (PDB: 4A4H)7. b Screening strategy starting with ~90,000 compound library. c Overview of AlphaScreen of full ~90,000 compound library (light gray) with DMSO (dark gray), positive control (quencher, yellow), and compound hits (red). d AlphaScreen percentage of DMSO control with SMNDC1/ sDMA-peptide vs crosslinking peptide. Remaining hits marked in red. e–k Chemical structure and AlphaScreen 9-point compound titration with SMNDC1/ sDMA-peptide (red) vs. SMN/ sDMA-peptide (yellow). Data presented as mean +/− SD (n = 2).
